Timing correction: IFF is scheduled to report after the market close today, Tuesday, August 4, 2026, with its earnings call at 9:00 a.m. ET on Wednesday, August 5—not tomorrow.
IFF enters Q2 with a solid operational start to 2026, but with a deliberately softer near-term setup than Q1. The key issue is not whether the company can show underlying growth—Q1 demonstrated broad-based volume improvement and margin expansion—but whether the anticipated Q2 pressure in Fine Fragrance, energy/logistics costs, and price-cost timing is contained enough to preserve full-year guidance.
The more consequential catalyst is portfolio-related: IFF’s June financing disclosure confirms that it has signed an agreement to sell Food Ingredients, expected to generate roughly $3.8 billion of net cash proceeds and close by the end of Q2 2027. Investors will want clarity on buyer, valuation, closing conditions, stranded-cost mitigation, and the post-sale capital-allocation framework.
At Q1, IFF explicitly indicated that Q2 adjusted operating EBITDA would be below Q1’s $568 million. Management attributed the sequential decline to:
That guidance sets a relatively clear near-term hurdle: a lower sequential EBITDA result is expected, so the market should focus more heavily on the quality of segment trends, the severity of Scent pressure, and whether management can credibly maintain its second-half recovery narrative.
| Q1 2026 metric | Result | Comparable, currency-neutral change |
|---|---|---|
| Sales | $2.74B | +3% |
| Adjusted operating EBITDA | $568M | +8% |
| Adjusted EBITDA margin | 20.7% | +110 bps |
| Adjusted EPS ex-amortization | $1.25 | vs. $1.20 in Q1 2025 |
| Free cash flow | $92M | +$144M YoY |
| Net debt / credit-adjusted EBITDA | 2.5x | Stable vs. Q4 2025 |
Q1’s most constructive feature was that all four operating segments delivered comparable currency-neutral sales growth. Taste, Food Ingredients, and Health & Biosciences also posted strong profit growth, leaving Scent as the principal weak spot.
| Segment | Q1 2026 sales growth* | Q1 EBITDA growth* | Q2 focus |
|---|---|---|---|
| Taste | +2% | +18% | Sustainability of margin gains; volume, pricing, and productivity all helped in Q1, but management cautioned that Q1’s degree of operating leverage should normalize. |
| Food Ingredients | +3% | +12% | Continued standalone improvement and, more importantly, transaction details. Q1 EBITDA margin was 13.6%; management previously targeted further progress. |
| Health & Biosciences | +5% | +7% | Whether the health/probiotics turnaround is beginning to emerge. Management had expected this business to be roughly flat in 1H, with improvement in 2H and acceleration in 2027. |
| Scent | +1% | -2% | The crucial swing factor. Watch Fine Fragrance exposure to the Middle East, Consumer Fragrance momentum, and ongoing commodity Fragrance Ingredients pressure. |
*Comparable, currency-neutral basis.
Scent was the only Q1 segment with declining EBITDA, despite sales growth. The drivers were unfavorable price-cost dynamics in Fragrance Ingredients and commodity competition, while Fine Fragrance and Consumer Fragrance were healthier.
For Q2, the Middle East disruption adds a second problem: management expects lower Fine Fragrance volume and adverse mix because of weaker regional demand and customers’ temporary packaging/supply-chain constraints. The key questions are:
A contained Scent miss paired with intact full-year guidance would likely be manageable. A broader deterioration in Fine Fragrance or a weaker outlook for price recovery would be more concerning.
IFF said Q2 would absorb the initial cost shock from higher energy and logistics before its pricing actions are fully implemented. Management expects that pressure to ease through the second half as surcharges and broader price actions take effect.
This makes the earnings call especially important. Investors should listen for:
IFF’s full-year plan still assumes pricing and productivity can offset the inflation challenge, but the Q2 result will show the size of the temporary margin trough.
In June, IFF disclosed a signed agreement to sell the Food Ingredients business. The company expects roughly $3.8 billion in net cash proceeds, with closing expected by the end of Q2 2027. Its related $1 billion delayed-draw term loan is intended to refinance €800 million of notes due in September 2026; proceeds from the Food Ingredients sale are required to prepay the facility.
This is strategically significant:
The Q2 report may or may not disclose the buyer or headline enterprise value, but investors should expect more detail on economics, timetable, regulatory approvals, transition services, and expected stranded costs.
Q1 Health & Biosciences was strong overall, led by Animal Nutrition and Food Biosciences. However, the company has repeatedly identified its health business—particularly probiotics—as an area that requires commercial and innovation improvement.
Management’s stated framework has been:
The Q2 read-through matters less for immediate earnings than for confidence in that medium-term growth algorithm. Any evidence of improving order pipelines, customer wins, or new-product traction would help validate the thesis.
IFF reaffirmed full-year 2026 guidance in May:
| 2026 guidance | Range |
|---|---|
| Sales | $10.5B–$10.8B |
| Comparable currency-neutral sales growth | +1% to +4% |
| Adjusted operating EBITDA | $2.05B–$2.15B |
| Comparable currency-neutral EBITDA growth | +3% to +8% |
| FX impact on sales growth | Approximately +1 pt |
| Divestiture impact on sales and EBITDA growth | Approximately -5 pts |
Maintaining that guidance after a softer Q2 would be constructive, but investors will need to judge how much of the recovery is pushed into the second half. The bull case is that Q1 outperformance, productivity, and progressively effective pricing more than compensate for a temporary Q2 Scent and cost headwind. The bear case is that weak Fine Fragrance, delayed price realization, and commodity fragrance pressure cause the recovery to become too back-half weighted.
IFF’s balance sheet is materially improved from prior years. In Q1, gross debt was $5.85 billion, cash was $562 million, and net leverage was 2.5x. Free cash flow improved sharply year over year, although Q1’s $92 million remained modest in absolute terms given seasonality and working-capital demands.
Watch for:
IFF closed at $80.60 on August 3, up about 13.9% since the May 5 Q1 release and roughly 18.5% year to date. It remains about 3.9% below its July 2 closing high of $83.83.
That performance suggests the market has already rewarded the Q1 execution improvement and the clearer portfolio path. As a result, simply meeting a lowered Q2 cadence may not be sufficient: investors are likely looking for reassurance that the second-half improvement, Food Ingredients transaction, and longer-term Health & Biosciences recovery remain on track.
Investment view into the print: IFF’s Q2 is primarily a confidence test rather than a pure beat-or-miss quarter. The report needs to show that the expected Q2 EBITDA trough is temporary, that price-cost recovery is underway, and that the Food Ingredients sale will unlock value without creating an overly complicated or cash-consuming transition.